Please assess the completion status of the following clinical trial:

Trial Title: Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Potential candidate for HCT.~* Histologically confirmed diagnosis by pathologic review of previous diagnosis of high-risk myelodysplastic syndrome (MDS): International Prognostic Scoring System (IPSS) \> 1 or AML-MDS or treatment related MDS.~* Serum bilirubin levels ≤1.5 times the upper limit of the normal (ULN) range for the laboratory. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis; Serum glutamic-oxaloacetic transaminase (SGOT) \[aspartate aminotransferase (AST)\] or serum glutamic pyruvic transaminase (SGPT) \[alanine aminotransferase (ALT)\] levels ≤2 x ULN.~* Serum creatinine levels ≤1.5 x ULN~* Karnofsky performance status greater or equal to 70%~* Signed informed consent form in accordance with institutional policies~Exclusion Criteria:~* Known or suspected hypersensitivity to Vidaza or mannitol~* Pregnant or lactating women~* Human immunodeficiency virus (HIV) or seropositive, confirmed by nucleic acid amplification testing (NAT)~* Active central nervous system (CNS) malignancy~* Active infection~* History or presence of primary hepatoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Combined Therapy (Type: EXPERIMENTAL): 5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).